At the end of her first day on the job as CEO of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, W. Kimryn Rathmell reflected on her decision to take the CEO job at the third largest cancer hospital in the United States.

We catch up with Kimryn Rathmell on her first day as CEO at OSUCCC – James

Pfizer seeks to improve breast cancer outcomes in Sub-Saharan Africa
With help from Conquer Cancer’s EveryGrant and ASCO’s Sub-Saharan Africa Regional Council, Pfizer awards grants to seven countries

The other side of the patient portal: Reflections from a cancer center leader

Surviving cancer is often not a patient’s most challenging battle

Podcasts

In The Headlines: Kimryn Rathmell, ASCO, and “an important time in cancer research”

Cancer Policy

A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”

RFK Jr. floats the idea of barring government scientists from publishing in leading medical journals due to “corruption”

Trump releases executive order that demands “Restoring Gold Standard Science”

U.S. halts foreign student visas, Rubio vows to revoke visas of students from China

MAHA report “Making our Children Healthy Again” focuses on ultraprocessed foods and is mum on tobacco

In Brief

CAR T Vision Coalition launches with goal of doubling patients treated with the curative potential of CAR T-cell therapy by 2030

Abu-Rustum, Burt Nabors, Styler, Thompson receive 2025 NCCN awards

KU Cancer Center breaks ground for new complex

Fred Hutch opens science learning lab for students

Clinical Roundup

Most Americans unaware of cancer risks associated with drinking alcohol

Efti + radiotherapy + Keytruda regimen meets primary endpoint in phase II study in soft tissue sarcoma

Wildfire pollution may lower survival of lung cancer patients

New biomarker may guide best use of KRAS inhibitors in lung cancer

Targeted strategy prevents untreatable nerve pain caused by chemotherapy

Drugs & Targets

FDA grants priority review for sevabertinib in HER2-mutant NSCLC

Alligator Bioscience announces European orphan drug designation for HLX22 in gastric cancer

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login